These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 11772314)

  • 1. Compounds in development to combat hyperphosphataemia.
    Ritz E; Hergesell O
    Expert Opin Investig Drugs; 2001 Dec; 10(12):2185-90. PubMed ID: 11772314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of disturbances of calcium and phosphate metabolism in chronic renal insufficiency, with emphasis on the control of hyperphosphataemia.
    Locatelli F; Cannata-Andía JB; Drüeke TB; Hörl WH; Fouque D; Heimburger O; Ritz E
    Nephrol Dial Transplant; 2002 May; 17(5):723-31. PubMed ID: 11981055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperphosphataemia in renal failure: causes, consequences and current management.
    Albaaj F; Hutchison A
    Drugs; 2003; 63(6):577-96. PubMed ID: 12656655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of new phosphate binders for chronic renal failure.
    Loghman-Adham M
    Drug Saf; 2003; 26(15):1093-115. PubMed ID: 14640773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral phosphate binders for the management of serum phosphate levels in dialysis patients.
    Mohammed I; Hutchison AJ
    J Ren Care; 2009 Mar; 35 Suppl 1():65-70. PubMed ID: 19222734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphate binders on iron basis: a new perspective?
    Hergesell O; Ritz E
    Kidney Int Suppl; 1999 Dec; 73():S42-5. PubMed ID: 10633463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of hyperphosphataemia in dialysis patients: role of phosphate binders in the elderly.
    Lorenzo Sellares V; Torres Ramírez A
    Drugs Aging; 2004; 21(3):153-65. PubMed ID: 14979734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calcium acetate versus calcium carbonate as phosphate-binding agents in chronic haemodialysis.
    Pflanz S; Henderson IS; McElduff N; Jones MC
    Nephrol Dial Transplant; 1994; 9(8):1121-4. PubMed ID: 7800211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphate binder usage in kidney failure patients.
    Bleyer AJ
    Expert Opin Pharmacother; 2003 Jun; 4(6):941-7. PubMed ID: 12783590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyperphosphataemia and treatment with sevelamer in haemodialysis patients.
    Cizman B
    Nephrol Dial Transplant; 2003 Jul; 18 Suppl 5():v47-9. PubMed ID: 12817070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hyperphosphataemia as a cardiovascular risk factor -- how to manage the problem.
    Cannata-Andía JB; Rodríguez-García M
    Nephrol Dial Transplant; 2002; 17 Suppl 11():16-9. PubMed ID: 12386251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone health and vascular calcification relationships in chronic kidney disease.
    Spasovski GB
    Int Urol Nephrol; 2007; 39(4):1209-16. PubMed ID: 17899431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypercalcaemia, hypermagnesaemia, hyperphosphataemia and hyperaluminaemia in CAPD: improvement in serum biochemistry by reduction in dialysate calcium and magnesium concentrations.
    Hutchison AJ; Were AJ; Boulton HF; Mawer EB; Laing I; Gokal R
    Nephron; 1996; 72(1):52-8. PubMed ID: 8903861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sevelamer carbonate lowers serum phosphorus effectively in haemodialysis patients: a randomized, double-blind, placebo-controlled, dose-titration study.
    Chen N; Wu X; Ding X; Mei C; Fu P; Jiang G; Li X; Chen J; Liu B; La Y; Hou F; Ni Z; Fu J; Xing C; Yu X; Huang C; Zuo L; Wang L; Hunter J; Dillon M; Plone M; Neylan J
    Nephrol Dial Transplant; 2014 Jan; 29(1):152-60. PubMed ID: 24151017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and side-effect profile of sevelamer hydrochloride used in combination with conventional phosphate binders.
    Sturtevant JM; Hawley CM; Reiger K; Johnson DW; Campbell SB; Burke JR; Bofinger A; Isbel NM
    Nephrology (Carlton); 2004 Dec; 9(6):406-13. PubMed ID: 15663645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving phosphate-binder therapy as a way forward.
    Hutchison AJ
    Nephrol Dial Transplant; 2004 Mar; 19 Suppl 1():i19-24. PubMed ID: 15126650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of hypercalcaemia in haemodialysis patients.
    Pascual N; Andrea C; Zaleski M; Hernandez J; Goicoechea M
    EDTNA ERCA J; 1997; 23(3):48-50. PubMed ID: 9664010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Slowing the progression of vascular calcification in hemodialysis.
    Chertow GM
    J Am Soc Nephrol; 2003 Sep; 14(9 Suppl 4):S310-4. PubMed ID: 12939387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of morbidity and mortality data related to cardiovascular calcification from calcium-containing phosphate binder use in patients undergoing hemodialysis.
    Mason MA; Shepler BM
    Pharmacotherapy; 2010 Jul; 30(7):741-8. PubMed ID: 20575637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.